Sarda Proteins Rebrands to Fresita Proteins, Boosts Capital to ₹100 Crore

Shareholders of Sarda Proteins Limited have approved a significant corporate overhaul, including a name change to Fresita Proteins Limited and a substantial increase in authorized capital. The company's authorized share capital has been raised from ₹13 crore to ₹100 crore.

What just happened

Shareholders approved changing the company's name to 'Fresita Proteins Limited' and increasing authorized capital from ₹13 crore to ₹100 crore. The company also altered its main object clause and restructured its board with new appointments.

Why this matters

This comprehensive rebranding and capital infusion signals a strategic pivot for the company, preparing it for potential future expansion and corporate restructuring activities. The board changes indicate a new management direction.

The backstory

Sarda Proteins Limited, previously focused on protein-related products, is undergoing a transformation. The recent Extraordinary General Meeting (EGM) approved these fundamental changes to its identity and structure.

What changes now

The company will officially operate as Fresita Proteins Limited. The increased capital provides financial flexibility for future growth initiatives. New leadership is in place to steer the company forward.

Risks to watch

Investors should await clarity on the specific business expansion plans and how effectively the new management will leverage the increased capital and altered objectives.

Peer comparison

[Peer comparison data not available in the filing.]

Context metrics (time-bound)

• Authorized capital increased from ₹13 crore to ₹100 crore.
• New statutory auditors appointed for a five-year term from April 1, 2026, to March 31, 2031.

What to track next

Future disclosures regarding the company's expansion strategy and the utilization of its enhanced capital base will be crucial for investors.